MONEY20/20
Money20/20, the world’s leading fintech show and the place where money does business, unveils its agenda for its upcoming Europe show in Amsterdam, 4-6 June. 350+ speakers are expected to take the stage in Amsterdam this year including C-suite executives from global banks such as Deutsche Bank and ING; fintech players such as Adyen and Revolut, senior representatives from the European Central Bank and the European Commission, and blockchain solution providers such as Ripple. The show promises an amalgamation of expertise, from the Wirecard whistleblower Pav Gill to tech evangelist Prince Constantijn van Oranje-Nassau of the Netherlands.
Under the theme of ‘Human X Machine’, Money20/20 Europe 2024 will explore the dynamic relationship between humans and intelligent machines, focusing on how the partnership between artificial and human intelligence will forge a new era in finance. In line with this, Money20/20 Europe also welcomes the CEOs of AI firms including Mistral AI, Datasnipper and Deeploy, alongside executives from the world of cryptocurrency including Kraken and Fireblocks. Nvidia and AWS are back again co-hosting a summit with Money20/20 deep diving into AI.
Scarlett Sieber, Money20/20's Chief Strategy & Growth Officer, emphasised the significance of this year's theme, saying, "I’m delighted to welcome such esteemed powerhouses in the world of finance to what promises to be our biggest and most impactful show in Europe yet. As I will discuss with Former French President François Hollande in our fireside chat, Human X Machine encapsulates the essence of our rapidly evolving financial landscape and underscores the critical intersection of human ingenuity and artificial intelligence in shaping our financial future. The power of the Money20/20 platform is that the collective ecosystem of money at the most senior level comes together to have active discussions on the most important topics, breaking news, and work together to pave the way for a more resilient and inclusive financial ecosystem.”
Pav Gill, the Wirecard whistleblower, and one of Money20/20 Europe’s keynote speakers said, "Speaking at Money20/20 Europe is more than an opportunity; it's a reflection of a journey that took me from the heart of the Wirecard scandal to the helm of Confide. Unveiling one of finance's largest deceptions wasn't just about exposing truths; it was about sparking change. At Confide, we're building the future of business integrity, using technology to ensure that the lessons learned from Wirecard and the many other scandals pave the way for a more accountable and transparent industry. I look forward to sharing this mission and inspiring action towards a culture where ethics and technology intersect to create safer business environments for all.”
Sessions at Money20/20 Europe will revolve around five key topic areas within the show’s Human X Machine theme. They are as follows:
- A Customer Universe of One: Finance is becoming a Universe of One; A place where hyper-personalisation occurs at a microscopic level across every touchpoint.
- The Age of Atomic Finance: The Universe of One is made possible by monumental technological advancements, from artificial intelligence and cryptography to quantum computing. These leaps in technology have delivered atomic-level precision, unlocking the potential for a Universe of One.
- Meet the Architects: From the leaders of trailblazing startups to changemakers in agile incumbents, we’ll showcase the architects of the new dawn; the visionaries who create new landscapes for our financial futures.
- Signal Vs Noise: The pace of financial innovation continues accelerating, fueled by emerging technologies like AI, blockchain, and Web3. Yet visionary breakthroughs live alongside hype-driven tangents. We need voices committed to elevating discourse and realising technology’s potential through innovation geared towards progress.
- The Business of Money: Hear from founders, key decision makers, consultants, investors, and disruptors. We’ll delve into the actions that led to success, and just as crucially we’ll carry out an audit on the activities that produced undesirable outcomes.
The Money20/20 Europe agenda can be found here, while the lineup of confirmed speakers can be found here.
Media who would like to attend Money20/20 Europe can register for a complimentary press pass here.
About Money20/20
Launched by industry insiders in 2012, Money20/20 has rapidly become the heartbeat of the global fintech ecosystem. Over the last decade, the most innovative, fast-moving ideas and companies have driven their growth on our platform. Mastercard, Airwallex, J.P. Morgan, SHIELD, GCash, Stripe, Google, Marqeta, VISA, Adyen, Checkout.com and more make transformational deals and raise their global profile with us. Money20/20 attracts leaders from the world’s greatest VC firms, banks, regulators and media platforms: convening to cut industry-shaping deals, build world-changing partnerships and unlock future-defining opportunities in Bangkok (23-25 April 2024), Amsterdam (4-6 June 2024) and Las Vegas (27-30 October 2024). Money20/20 also recently launched Twentyfold, a Digital Intelligence product containing the deepest and widest repository of fintech startup data in the world. Money20/20 is where the world’s fintech leaders convene to grow their businesses. Money20/20 is part of Ascential plc. Follow Money20/20 on X and LinkedIn for show developments and updates. We’re Where Money Does Business.
Follow Money20/20 on Twitter for show developments and updates.
You can also find us on LinkedIn at Money20/20.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416620432/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
